NO20081267L - Fremgangsmåte for fremstilling av 4-(4-brom-2-fluoranilino)-6-metoksy-7-(1-metylpiperidin-4-ylmetoksy)kinazolin, ZD6474 - Google Patents

Fremgangsmåte for fremstilling av 4-(4-brom-2-fluoranilino)-6-metoksy-7-(1-metylpiperidin-4-ylmetoksy)kinazolin, ZD6474

Info

Publication number
NO20081267L
NO20081267L NO20081267A NO20081267A NO20081267L NO 20081267 L NO20081267 L NO 20081267L NO 20081267 A NO20081267 A NO 20081267A NO 20081267 A NO20081267 A NO 20081267A NO 20081267 L NO20081267 L NO 20081267L
Authority
NO
Norway
Prior art keywords
fluoroanilino
ylmethoxy
methylpiperidin
quinazoline
bromo
Prior art date
Application number
NO20081267A
Other languages
English (en)
Other versions
NO342152B1 (no
Inventor
Zakariya Patel
Jørgen Blixt
Michael David Golden
Philip Hogan
David Michael Glanville Martin
Francis Joseph Montgomery
John David Pittam
George Joseph Sependa
Christopher John Squire
Nicholas Cartwright Alexander Wright
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081267(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of NO20081267L publication Critical patent/NO20081267L/no
Publication of NO342152B1 publication Critical patent/NO342152B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20081267A 2005-09-30 2008-03-11 Fremgangsmåte for fremstilling av 4-(4-brom-2-fluoranilino)-6-metoksy-7-(1-metylpiperidin-4-ylmetoksy)kinazolin, ZD6474 NO342152B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process
PCT/GB2006/003587 WO2007036713A2 (en) 2005-09-30 2006-09-27 Chemical process

Publications (2)

Publication Number Publication Date
NO20081267L true NO20081267L (no) 2008-04-30
NO342152B1 NO342152B1 (no) 2018-04-03

Family

ID=35395001

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081267A NO342152B1 (no) 2005-09-30 2008-03-11 Fremgangsmåte for fremstilling av 4-(4-brom-2-fluoranilino)-6-metoksy-7-(1-metylpiperidin-4-ylmetoksy)kinazolin, ZD6474

Country Status (32)

Country Link
US (8) US8163926B2 (no)
EP (2) EP2053048B8 (no)
JP (2) JP5213715B2 (no)
KR (1) KR101307641B1 (no)
CN (3) CN102503898B (no)
AR (1) AR055671A1 (no)
AT (2) ATE481399T1 (no)
AU (1) AU2006296367B2 (no)
BR (1) BRPI0616715A2 (no)
CA (2) CA2745829C (no)
CY (2) CY1110275T1 (no)
DE (2) DE602006010428D1 (no)
DK (2) DK2053048T3 (no)
ES (2) ES2350513T3 (no)
GB (1) GB0519879D0 (no)
HK (2) HK1122553A1 (no)
HR (2) HRP20100019T1 (no)
IL (2) IL190172A (no)
ME (2) ME01466B (no)
MY (2) MY145540A (no)
NO (1) NO342152B1 (no)
NZ (2) NZ566566A (no)
PL (2) PL2053048T3 (no)
PT (2) PT1943240E (no)
RS (2) RS51515B (no)
RU (1) RU2448102C2 (no)
SG (1) SG165416A1 (no)
SI (2) SI2053048T1 (no)
TW (2) TWI328580B (no)
UY (1) UY29824A1 (no)
WO (1) WO2007036713A2 (no)
ZA (1) ZA200802416B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2473572C (en) * 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US7851623B2 (en) * 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
ES2547902T3 (es) * 2011-09-01 2015-10-09 Symrise Ag Procedimiento para la preparación de derivados de indanona
KR20150043465A (ko) * 2012-08-15 2015-04-22 글락소 그룹 리미티드 화학 공정
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) * 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
CA2195129C (en) 1991-03-28 2002-09-10 Anabella Villalobos Substituted piperidine intermediates for producing heterocyclic-cyclic amine derivatives capable of inhibiting cholinesterase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
AU680004B2 (en) * 1993-05-26 1997-07-17 Syntex (U.S.A.) Inc. Novel 1-phenylalkanone 5-HT4 receptor ligands
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE170174T1 (de) 1994-01-13 1998-09-15 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin- antagonisten
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
ATE468339T1 (de) 2001-12-20 2010-06-15 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
EP1481971B1 (en) 2002-02-06 2011-11-16 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
MXPA05001458A (es) 2002-08-09 2005-06-06 Astrazeneca Ab Combinacion de zd6474, un inhibidor del receptor del factor de crecimiento endotelial vascular, con radioterapia en tratamiento de cancer.
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
EP1592423B1 (en) 2003-02-13 2011-04-20 AstraZeneca AB Combination therapy of zd6474 with 5-fu and/or cpt-11
CA2531862C (en) 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Also Published As

Publication number Publication date
US20160185754A1 (en) 2016-06-30
ZA200802416B (en) 2009-01-28
CY1110275T1 (el) 2015-01-14
CN101277948B (zh) 2013-03-13
RU2008116573A (ru) 2009-11-10
NZ593930A (en) 2013-02-22
AU2006296367B2 (en) 2011-08-11
HRP20100620T1 (hr) 2010-12-31
DE602006010428D1 (de) 2009-12-24
RS51263B (sr) 2010-12-31
CY1110887T1 (el) 2015-06-10
US20120095229A1 (en) 2012-04-19
NO342152B1 (no) 2018-04-03
PT1943240E (pt) 2010-01-11
CA2745829A1 (en) 2007-04-05
US20240150317A1 (en) 2024-05-09
WO2007036713A2 (en) 2007-04-05
IL227574A (en) 2015-08-31
CN102503898B (zh) 2015-03-25
TW201018660A (en) 2010-05-16
US20180118716A1 (en) 2018-05-03
IL190172A (en) 2014-05-28
US20140378684A1 (en) 2014-12-25
JP5213715B2 (ja) 2013-06-19
SI1943240T1 (sl) 2010-02-26
WO2007036713A3 (en) 2007-06-14
ATE481399T1 (de) 2010-10-15
TWI424991B (zh) 2014-02-01
CN101277948A (zh) 2008-10-01
RS51515B (en) 2011-06-30
US9815816B2 (en) 2017-11-14
US8865899B2 (en) 2014-10-21
AU2006296367A1 (en) 2007-04-05
MY145540A (en) 2012-02-29
NZ566566A (en) 2011-08-26
CA2624045A1 (en) 2007-04-05
MY149834A (en) 2013-10-31
GB0519879D0 (en) 2005-11-09
RU2448102C2 (ru) 2012-04-20
EP1943240A2 (en) 2008-07-16
DK1943240T3 (da) 2010-03-01
JP2009510039A (ja) 2009-03-12
SI2053048T1 (sl) 2010-12-31
US20220033377A1 (en) 2022-02-03
JP5654546B2 (ja) 2015-01-14
CN102503898A (zh) 2012-06-20
US20090203905A1 (en) 2009-08-13
CN102503933B (zh) 2014-06-25
EP2053048B1 (en) 2010-09-15
CA2745829C (en) 2013-07-02
CA2624045C (en) 2012-05-22
KR20080049114A (ko) 2008-06-03
SG165416A1 (en) 2010-10-28
US8163926B2 (en) 2012-04-24
EP1943240B1 (en) 2009-11-11
HK1130478A1 (en) 2009-12-31
CN102503933A (zh) 2012-06-20
DE602006017004D1 (de) 2010-10-28
ME01531B (me) 2014-04-20
PL2053048T3 (pl) 2011-03-31
PL1943240T3 (pl) 2010-04-30
EP2053048A1 (en) 2009-04-29
UY29824A1 (es) 2007-04-30
DK2053048T3 (da) 2010-11-29
PT2053048E (pt) 2010-11-10
JP2013063998A (ja) 2013-04-11
US20190263782A1 (en) 2019-08-29
HRP20100019T1 (hr) 2010-02-28
ME01466B (me) 2014-04-20
ATE448218T1 (de) 2009-11-15
ES2350513T3 (es) 2011-01-24
TW200745036A (en) 2007-12-16
TWI328580B (en) 2010-08-11
ES2335435T3 (es) 2010-03-26
HK1122553A1 (en) 2009-05-22
BRPI0616715A2 (pt) 2011-06-28
KR101307641B1 (ko) 2013-09-12
IL190172A0 (en) 2008-08-07
AR055671A1 (es) 2007-08-29
EP2053048B8 (en) 2011-09-21
US10344015B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
NO20081267L (no) Fremgangsmåte for fremstilling av 4-(4-brom-2-fluoranilino)-6-metoksy-7-(1-metylpiperidin-4-ylmetoksy)kinazolin, ZD6474
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
ATE537829T1 (de) Therapeutische verwendung von verbindungen mit kombinierter sert-, 5-ht3 und 5-ht1a-aktivität
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
BRPI0906020A2 (pt) Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento
ATE550336T1 (de) Ä1,2,3ü-triazolyl-substituierte chinoline und coumarine als leukotrien-biosynthese-hemmer
EP2540706A3 (en) Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
CL2011002925A1 (es) Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1.
DK1838697T3 (da) Fremgangsmåder til at fremstille 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)-piperidin-1-carboxylsyre-derivater og relaterede forbindelser
NO20052262D0 (no) Fremgangsmate til fremstilling av 4-substituerte 2,2,6,6-tetrametyl-piperidin-N-oksy- og 2,2,6,6-tetrametyl-piperidin-N-hydroksy-forbindelser
ITTO20110630A1 (it) Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
EA201001773A1 (ru) Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
ATE521603T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
DE602007001779D1 (de) Neuartige pyridinylaminalkylen- und pyridinyloxalkylen-cyclopropanamine, herstellungsverfahren dafür und pharmazeutische zusammensetzungen damit
IL190010A0 (en) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)
DK1906921T3 (da) Klar farmaceutisk, vandig mikroemulsion omfattende propofol og fremgangsmåde til fremstilling
WO2010122340A3 (en) Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1-(n-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline
WO2010068920A3 (en) Diaminoquinazoline inhibitors of dihydrofolate reductase
CL2007003410A1 (es) Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
FI20050586A0 (fi) Menetelmä N-[4-(4-fluorofenyyli)-5-formyyli-6-isopropyylipyrimidiini-2-yyli]-N-metyylimetaanisulfonamidin valmistamiseksi
ATE499358T1 (de) Synthese von piperazinen, piperidinen und verwandten verbindungen
IT1392711B1 (it) Complesso di persiana ed inferriata per serramenti di edificio.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GENZYME CORPORATION, US

MM1K Lapsed by not paying the annual fees